GlassScriptPhysician profile
Maritza I Perez
NPI 1831140730
$25,944.83
in general payments reported to CMS, 2019-2025
31 companies · $3,178 in 2025
The $3,178 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,464 · 2020: $427 · 2021: $596 · 2022: $609 · 2023: $4,965 · 2024: $14K · 2025: $3,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $786 · Food and Beverage: $457 · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,537.50 |
| Travel and Lodging | $786.21 |
| Food and Beverage | $456.61 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,580.95 | 2021-2024 | Libtayo, Dupixent |
| Abbvie INC. | $3,156.50 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,403.26 | 2019-2025 | Nemluvio |
| Merz North America, INC. | $631.60 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $365.77 | 2019-2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $268.43 | 2019-2024 | |
| Glaxosmithkline, LLC. | $170.35 | 2020-2023 | Bexsero, Pediarix, Rotarix |
| Janssen Scientific Affairs, LLC | $141.28 | 2022 | |
| Vyne Pharmaceuticals INC. | $136.15 | 2020 | |
| Journey Medical Corporation | $125.45 | 2020-2022 | |
| Pfizer INC. | $117.23 | 2019-2024 | |
| Genzyme Corporation | $106.82 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $102.58 | 2019-2021 | |
| Lilly USA, LLC | $84.65 | 2019 | |
| Leo Pharma INC. | $68.58 | 2019-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $67.83 | 2021 | |
| Paratek Pharmaceuticals, INC. | $58.56 | 2021 | |
| Allergan, INC. | $47.33 | 2019-2020 | |
| Sanofi Pasteur INC. | $45.63 | 2023-2024 | |
| Janssen Biotech, INC. | $41.73 | 2024 | Tremfya |
| Ucb, INC. | $33.91 | 2025 | Bimzelx |
| Nabriva Therapeutics, Plc | $32.07 | 2020-2021 | |
| Melinta Therapeutics, LLC | $26.19 | 2019 | |
| Epi Health, LLC | $20.76 | 2020 | |
| Merck Sharp & Dohme LLC | $18.48 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.07 | 2020 | |
| Organogenesis INC. | $17.57 | 2021 | |
| Almirall LLC | $16.70 | 2021 | |
| Encore Dermatology INC. | $14.86 | 2019 | |
| Strata Skin Sciences, INC. | $13.48 | 2019 | |
| Sebela Pharmaceuticals INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.